Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
May 04, 2021	PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first quarter 2020 - - DMD franchise net product revenue of $90 million; 32% increase over first quarter 2020 - - PTC has	Additional Formats
Apr 27, 2021	PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences SOUTH PLAINFIELD, N.J. , April 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: BofA Securities 2021 Virtual Health Care Conference Tuesday, May 11 th at 8:45 a.m.	Additional Formats
Apr 20, 2021	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021	Additional Formats
Apr 19, 2021	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"), each representing	Additional Formats
Apr 15, 2021	Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™ - Evrysdi increased survival and reduced need for permanent ventilation - SOUTH PLAINFIELD, N.J. , April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular	Additional Formats
Apr 14, 2021	PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing - Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge - SOUTH PLAINFIELD, N.J. , April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United	Additional Formats
Apr 07, 2021	PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures that get the best out	Additional Formats
Apr 07, 2021	PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an overview of PTC's	Additional Formats
Apr 01, 2021	PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ SOUTH PLAINFIELD, N.J. , April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi ™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.	Additional Formats
Mar 30, 2021	PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy - First and only at home treatment approved for SMA - - Proven efficacy in adults and children with SMA 2 months and older - SOUTH PLAINFIELD, N.J. , March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing	Additional Formats